ABOS (Acumen Pharmaceuticals, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ABOS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-17 | Derrell Porter | Director | MIXED | — | — |
| 2026-06-10 | Nathan B Fountain | Director | Sell | — | — |
| 2026-06-05 | John A III Stalfort | Director | A | — | — |
| 2026-06-05 | Nathan B Fountain | Director | A | — | — |
| 2026-06-05 | Kimberlee C Drapkin | Director | A | — | — |
| 2026-06-05 | Jeffrey L. Ives | Director | A | — | — |
| 2026-06-05 | Derrell Porter | Director | A | — | — |
| 2026-06-05 | Laura Stoppel | Director | A | — | — |
| 2026-06-05 | RA Capital Healthcare Fund LP | Director | A | — | — |
| 2026-06-05 | George Golumbeski | Director | A | — | — |
| 2026-03-18 | Rajeev M. Shah | Director | A | — | — |
| 2026-03-10 | Derek M Meisner | Chief Legal Officer & Corp Sec | MIXED | — | — |
| 2026-03-03 | Derek M Meisner | Chief Legal Officer & Corp Sec | MIXED | — | — |
| 2026-01-28 | Derek M Meisner | Chief Legal Officer & Corp Sec | MIXED | — | — |
| 2026-01-23 | Daniel Joseph OConnell | Chief Executive Officer | Sell | — | — |
| 2026-01-23 | Russell Barton | Chief Operating Officer | Sell | — | — |
| 2026-01-23 | Eric Siemers | Chief Medical Officer | Sell | — | — |
| 2026-01-23 | Derek M Meisner | Chief Legal Officer & Corp Sec | Sell | — | — |
| 2026-01-23 | Matt Zuga | CFO & Chief Business Officer | Sell | — | — |
| 2026-01-21 | Daniel Joseph OConnell | Chief Executive Officer | A | — | — |
| 2026-01-21 | Eric Siemers | Chief Medical Officer | A | — | — |
| 2026-01-21 | Matt Zuga | CFO & Chief Business Officer | A | — | — |
| 2026-01-21 | Derek M Meisner | Chief Legal Officer & Corp Sec | A | — | — |
| 2026-01-21 | Amy Schacterle | Chief Regulatory Officer | A | — | — |
| 2026-01-21 | Russell Barton | Chief Operating Officer | A | — | — |
| 2026-01-21 | James J. Doherty | President and CDO | A | — | — |
| 2026-01-12 | Matt Zuga | CFO & Chief Business Officer | Sell | — | — |
| 2026-01-12 | Russell Barton | Chief Operating Officer | Sell | — | — |
| 2026-01-12 | Derek M Meisner | Chief Legal Officer & Corp Sec | Sell | — | — |
| 2026-01-12 | Daniel Joseph OConnell | Chief Executive Officer | Sell | — | — |
| 2026-01-09 | James J. Doherty | President and CDO | Sell | — | — |
| 2026-01-09 | Amy Schacterle | Chief Regulatory Officer | Sell | — | — |
| 2026-01-07 | Eric Siemers | Chief Medical Officer | Sell | — | — |
| 2026-01-07 | Russell Barton | Chief Operating Officer | Sell | — | — |
| 2026-01-07 | Matt Zuga | CFO & Chief Business Officer | Sell | — | — |
| 2026-01-07 | Daniel Joseph OConnell | Chief Executive Officer | Sell | — | — |
| 2026-01-07 | Derek M Meisner | Chief Legal Officer & Corp Sec | Sell | — | — |
| 2025-11-10 | George Golumbeski | Director | A | — | — |
| 2025-06-05 | Jeffrey L. Ives | Director | A | — | — |
| 2025-06-05 | Kimberlee C Drapkin | Director | A | — | — |
| 2025-06-05 | Nathan B Fountain | Director | A | — | — |
| 2025-06-05 | John A III Stalfort | Director | A | — | — |
| 2025-06-05 | Laura Stoppel | Director | A | — | — |
| 2025-06-05 | Derrell Porter | Director | A | — | — |
| 2025-06-05 | Rajeev M. Shah | Director | A | — | — |
| 2025-01-23 | Daniel Joseph OConnell | Chief Executive Officer | Sell | — | — |
| 2025-01-23 | Derek M Meisner | Chief Legal Officer & Corp Sec | Sell | — | — |
| 2025-01-23 | Matt Zuga | CFO & Chief Business Officer | Sell | — | — |
| 2025-01-23 | Russell Barton | Chief Operating Officer | Sell | — | — |
| 2025-01-23 | Eric Siemers | Chief Medical Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 19,103,785 | — |
| — | 10%+ Owner | 3,040,193 | — |
| — | 10%+ Owner | 3,040,193 | — |
| — | 10%+ Owner | 1,124,729 | — |
| — | Chief Executive Officer | 881,275 | — |
| — | Director | 352,219 | — |
| — | CFO & Chief Business Officer | 304,924 | — |
| — | Chief Medical Officer | 255,371 | — |
| — | President and CDO | 220,900 | — |
| — | Chief Operating Officer | 205,092 | — |
| — | Chief Legal Officer & Corp Sec | 173,999 | — |
| — | Chief Regulatory Officer | 92,303 | — |
| — | Director | 48,300 | — |
| — | Director | 48,300 | — |
| — | Director | 48,300 | — |
| — | Director | 48,300 | — |
| — | Director | 48,150 | — |
| — | Director | 35,500 | — |
| — | Director | 35,500 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ABOS quote page; the site-wide leaderboard is on the insider transactions hub.